Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA.
Bone Marrow Transplant. 2012 Sep;47(9):1147-53. doi: 10.1038/bmt.2011.175. Epub 2011 Aug 29.
Waldenström macroglobulinemia is a highly chemosensitive lymphoplasmacytic lymphoma with response rates of 90% to first-line chemotherapy. The fraction of patients undergoing stem cell transplant for this disorder appears to be lower than that of patients with multiple myeloma. The indolent nature and favorable genetic profile should make Waldenström an ideal disorder for autologous stem cell transplant, with high response rates that are durable. We review the literature on autologous and allogeneic transplants for Waldenström macroglobulinemia and conclude that autologous transplant is effective and underutilized in the management of this disorder. Allogeneic transplant should be considered investigational and used only in the context of a clinical trial or when other chemotherapeutic options have been exhausted.
华氏巨球蛋白血症是一种高度化疗敏感的淋巴浆细胞淋巴瘤，一线化疗的缓解率为 90%。接受这种疾病干细胞移植的患者比例似乎低于多发性骨髓瘤患者。惰性特征和有利的遗传特征应该使华氏巨球蛋白血症成为自体干细胞移植的理想疾病，具有持久的高反应率。我们回顾了关于华氏巨球蛋白血症的自体和同种异体移植的文献，并得出结论，自体移植在这种疾病的治疗中是有效的，但未得到充分利用。同种异体移植应被视为研究性的，仅在临床试验或其他化疗方案已用尽的情况下使用。
